Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib

Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases

(2014) Marcin R. Dzienis et al.   MELANOMA RESEARCH

The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions

(2013) Jack Murrell et al.   CANCER TREATMENT REVIEWS

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy

(2013) Aglaia Maleka et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib and radiation therapy in melanoma brain metastases

(2013) Ashwatha Narayana et al.   JOURNAL OF NEURO-ONCOLOGY

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib

(2013) Jee Min Lee et al.   MELANOMA RESEARCH

Brain metastases: pathobiology and emerging targeted therapies

(2012) Matthias Preusser et al.   ACTA NEUROPATHOLOGICA

The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases

(2012) D. Fortin   CURRENT CANCER DRUG TARGETS

Melanoma brain metastasis: overview of current management and emerging targeted therapies

(2012) Ekokobe Fonkem et al.   Expert Review of Neurotherapeutics

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation

(2012) Nicole M. Rochet et al.   MAYO CLINIC PROCEEDINGS

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

(2012) Selvi Durmus et al.   MOLECULAR PHARMACEUTICS

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Prognostic factors for survival in melanoma patients with brain metastases

(2010) Michael A. Davies et al.   CANCER

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

(2010) Keiran S.M. Smalley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

(2008) C. Montagut et al.   CANCER RESEARCH